Jefferies Upgrades Enanta Pharma to Buy, Raises Price Target to $20

Benzinga · 10/01/2025 16:27
Jefferies analyst Akash Tewari upgrades Enanta Pharma (NASDAQ:ENTA) from Hold to Buy and raises the price target from $14 to $20.